Clinical and laboratory variables at baseline
| No cardiovascular death (n = 69) | Cardiovascular death (n = 54) | ||||||
|---|---|---|---|---|---|---|---|
| n (%) | Mean (SD) | 95% CI | n (%) | Mean (SD) | 95% CI | ||
| Age (years) | 69 | 58 (9) | 55 to 60 | 54 | 61 (7) | 59 to 63 | |
| Male | 53 (77) | 42 (78) | |||||
| Female | 16 (23) | 12 (22) | |||||
| Hypertension | 16 (23) | 21 (39) | |||||
| Diabetes mellitus | 9 (13) | 6 (11) | |||||
| Smoker | 25 (36) | 11 (20) | |||||
| Previous angina pectoris | 25 (36) | 41 (76) | |||||
| AST (units/l) | 63 | 4.3 (3.1) | 3.5 to 5.1 | 53 | 4.2 (3.3) | 3.3 to 5.1 | |
| Triglycerides (mmol/l) | 60 | 2.2 (1.1) | 1.9 to 2.5 | 45 | 2.0 (0.9) | 1.7 to 2.3 | |
| Cholesterol (mmol/l) | 61 | 7.1 (1.5) | 6.7 to 7.5 | 46 | 6.9 (1.2) | 6.5 to 7.3 | |
| DHEAS (μmol/l) | 69 | 6.0 (3.9) | 5.0 to 6.9 | 54 | 4.6 (2.7) | 3.8 to 5.3 | |
| SHBG (μmol/l) | 69 | 25 (14) | 21 to 28 | 54 | 26 (13) | 23 to 30 | |
| vWF (% of normal) | 69 | 138 (61) | 123 to 153 | 54 | 164 (52) | 150 to 178 | |
| vWF vo (% of normal) | 67 | 176 (59) | 161 to 190 | 54 | 221 (69) | 202 to 240 | |
| tPA activity (U/ml) | 69 | 0.09 (0.07) | 0.07 to 0.11 | 54 | 0.12 (0.13) | 0.08 to 0.16 | |
| tPA activity vo (U/ml) | 67 | 2.3 (2.9) | 1.6 to 3.0 | 54 | 1.7 (2.2) | 1.2 to 2.3 | |
| tPA mass conc (μg/l) | 69 | 11.0 (4.3) | 10.0 to 12.0 | 54 | 12.8 (5.4) | 11.4 to 14.3 | |
| tPA mass conc vo (μg/l) | 67 | 35 (23) | 29 to 40 | 54 | 40 (28) | 33 to 48 | |
| PAI-1 (U/ml) | 69 | 10.6 (7.1 | 8.9 to 12.3 | 54 | 9.1 (5.1) | 7.8 to 10.6 | |
AST, aspartate aminotransferase; DHEAS, dehydroepiandrosterone sulphate; SHBG, sexual hormone binding globulin; vWF von Willebrand factor; vo, after venous occlusion; tPA, tissue plasminogen activator; conc, concentration; PAI-1, plasminogen activator inhibitor.